Improving the Design of Pivotal Clinical Trials

Vinay K. Prasad, MD, MPH

H&O What are some typical flaws in the design of pivotal clinical trials? VP There are 5 common flaws in the design of pivotal clinical […]

Advances in Off-the-Shelf CAR T-Cell Therapy

Reuben Benjamin, MBBS, MRCP, FRCPath, PhD

H&O What is the manufacturing process for approved CAR T-cell therapies? RB Currently, the US Food and Drug Administration has approved 2 chimeric antigen receptor […]

Diagnosis and Treatment of Cold Agglutinin Disease

Catherine M. Broome, MD

H&O How common is cold agglutinin disease? CR Cold agglutinin disease is rare, with an estimated incidence of approximately 1 per million. H&O What causes […]

Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia

Shilpa Paul, PharmD, BCOP, Caitlin R. Rausch, PharmD, BCOP, Patrice E. Nasnas, MD, Hagop Kantarjian, MD, and Elias J. Jabbour, MD

Abstract: Patients with relapsed or refractory acute lymphoblastic leukemia (R/R ALL) have dismal outcomes, with survival of less than 6 months, and treatment options in […]

Update on Perioperative Systemic Therapy for Urothelial Carcinoma

Keren Rouvinov, MD, Elizabeth R. Plimack, MD, Matthew Zibelman, MD, Pooja Ghatalia, MD, and Daniel M. Geynisman, MD

Abstract: Level 1 evidence supports cisplatin-based neoadjuvant chemotherapy (NAC) in muscle-invasive urothelial bladder cancer (MIUBC). Recent data from small prospective trials with neoadjuvant immune checkpoint […]

My First Year in Practice

Pressing the Restart Button as a New Postgraduate From Fellowship: Year No. 1

Michael S. Humeniuk, MD

After 10 years of medical education, I had finally done it! I had finished my medical oncology and hematology fellowship at Duke University and started as […]

Letter From the Editor

Letter From the Editor: Talk to Me

Daniel J. George, MD

Medical communication is increasingly nonverbal. Electronic medical records, e-mail, texting, websites, search engines, and even social media all make us depend less than ever on the […]

Archive: March 2019

Drug Development